

26 Sep 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda's heels in first-line lung cancer; and a look at the market prospects for wet AMD.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 24 September 2021, including: an interview with the president of [Novartis AG](#) Pharma; [Biogen, Inc.](#) highlights its pipeline; standout comparative data for Enhertu in breast cancer; [Sanofi/Regeneron Pharmaceuticals, Inc.](#) nip at Keytruda's heels in first-line lung cancer; and a look at the market prospects for wet AMD.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Novartis's Tschudin On Launches, Drug Pricing And Lasting COVID Impacts](#)" - Scrip, 22 Sep, 2021.)

(Also see "[Looking Past Aduhelm, Biogen Puts Pipeline On Display](#)" - Scrip, 22 Sep, 2021.)

(Also see "[Enhertu Poised To Rewrite The Standard Of Care After ESMO](#)" - Scrip, 20 Sep, 2021.)

(Also see "[ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC](#)" - Scrip, 20 Sep, 2021.)

# SCRIP

CITELINE COMMERCIAL

(Also see "[Wet AMD Market Snapshot: A High-Growth Market Poised For Change](#)" - Scrip, 17 Sep, 2021.)

[Click here to explore this interactive content online](#) 